WCLC 2025 - Posters & ePosters-EP.03.08 Tumor Treating Fields (TTFields) Concomitant With Antiangiogenic Therapy in Non-Small Cell Lung Cancer in Vivo Model

EP.03.08 Tumor Treating Fields (TTFields) Concomitant With Antiangiogenic Therapy in Non-Small Cell Lung Cancer in Vivo Model

Back to course

Pdf Summary

This study investigated the effects of combining Tumor Treating Fields (TTFields) with docetaxel chemotherapy and an anti-VEGFR antibody (DC101) on non-small cell lung cancer (NSCLC) in a mouse model. NSCLC progression is closely linked to angiogenesis, and treatments targeting vascular endothelial growth factor receptors (VEGFR) like ramucirumab are approved in combination with docetaxel as second-line therapy. Angiogenesis inhibitors normalize tumor vasculature, improving drug delivery and immune infiltration. TTFields are electric fields disrupting cancer cell processes and are approved with docetaxel or immune checkpoint inhibitors for metastatic NSCLC after platinum therapy failure.<br /><br />In the study, C57Bl/6 mice with orthotopically implanted LL/2 lung carcinoma were treated with TTFields (150 kHz), docetaxel, and/or DC101 in various combinations. Tumor volume was monitored by MRI, and tumors were analyzed for vessel maturity (via CD31 and αSMA staining), tumor cell death (TUNEL assay), and immune cell infiltration (CD8 counts).<br /><br />Key findings include:<br /><br />1. The combination of TTFields, docetaxel, and DC101 significantly reduced tumor growth compared to monotherapies or dual therapies.<br />2. TTFields with docetaxel and DC101 enhanced blood vessel normalization, indicated by increased vessel maturity markers.<br />3. This triple combination elevated tumor cell death substantially.<br />4. It also increased infiltration of CD8+ immune cells into the tumor microenvironment.<br /><br />The results suggest that TTFields used alongside docetaxel and anti-VEGFR therapy synergistically improve treatment efficacy in NSCLC by normalizing vasculature, promoting immune cell infiltration, and increasing tumor cell death. This combined approach holds promise for advancing second-line treatment strategies in NSCLC patients.<br /><br />Presented at the 2025 World Conference on Lung Cancer, this study highlights the potential of integrating TTFields with established chemotherapies and antiangiogenic agents to enhance outcomes in lung cancer therapy.

Asset Subtitle

Anat Klein-Goldberg

Meta Tag

Speaker Anat Klein-Goldberg

Topic Tumor Biology – Translational Biology

Keywords

Tumor Treating Fields

TTFields

docetaxel chemotherapy

anti-VEGFR antibody

DC101

non-small cell lung cancer

NSCLC

angiogenesis inhibition

tumor vasculature normalization

immune cell infiltration